Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin: 2014-2025

Historic EBITDA Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -48.61%.

  • Viridian Therapeutics, Inc.\DE's EBITDA Margin rose 8740953.00% to -48.61% in Q3 2025 from the same period last year, while for Sep 2025 it was -427.38%, marking a year-over-year increase of 8436997.00%. This contributed to the annual value of -89,502.32% for FY2024, which is 1402270.00% down from last year.
  • Viridian Therapeutics, Inc.\DE's EBITDA Margin amounted to -48.61% in Q3 2025, which was up 99.96% from -134,548.00% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's EBITDA Margin's 5-year high stood at -48.61% during Q3 2025, with a 5-year trough of -134,548.00% in Q2 2025.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin had a median value of -87,458.14% in 2024 and averaged -83,409.32%.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin plummeted by 6,489,961bps in 2023 and then skyrocketed by 8,740,953bps in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin (Quarterly) stood at -13,598.13% in 2021, then tumbled by 2,948,282bps to -43,080.95% in 2022, then crashed by 4,922,183bps to -92,302.78% in 2023, then crashed by 1,973,472bps to -112,037.50% in 2024, then surged by 8,740,953bps to -48.61% in 2025.
  • Its last three reported values are -48.61% in Q3 2025, -134,548.00% for Q2 2025, and -120,356.94% during Q1 2025.